Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists ; volume:38 ; number:6 ; day:11 ; month:5 ; year:2021 ; pages:2821-2839 ; date:6.2021
Advances in therapy ; 38, Heft 6 (11.5.2021), 2821-2839, 6.2021
- Urheber
-
Ard, Jamy
Fitch, Angela
Fruh, Sharon
Herman, Lawrence
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01710-0
- URN
-
urn:nbn:de:101:1-2021100218581045789881
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ard, Jamy
- Fitch, Angela
- Fruh, Sharon
- Herman, Lawrence
- SpringerLink (Online service)
Ähnliche Objekte (12)
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes